{"id":153217,"date":"2025-12-11T14:48:10","date_gmt":"2025-12-11T14:48:10","guid":{"rendered":"https:\/\/kamucalisani.net\/?p=153217"},"modified":"2025-12-11T14:48:10","modified_gmt":"2025-12-11T14:48:10","slug":"biontechin-deneysel-akciger-kanseri-ilaci-en-riskli-grupta-olum-oranini-yariya-indirdi","status":"publish","type":"post","link":"https:\/\/kamucalisani.net\/index.php\/2025\/12\/11\/biontechin-deneysel-akciger-kanseri-ilaci-en-riskli-grupta-olum-oranini-yariya-indirdi\/","title":{"rendered":"BioNTech’in deneysel akci\u011fer kanseri ilac\u0131, en riskli grupta \u00f6l\u00fcm oran\u0131n\u0131 yar\u0131ya indirdi"},"content":{"rendered":"

<\/span> Geli\u015ftirdi\u011fi Covid a\u015f\u0131s\u0131yla bir d\u00f6nem ad\u0131ndan s\u0131k\u00e7a s\u00f6z ettiren Alman biyoteknoloji \u015firketi BioNTech<\/strong>, \u015fimdi de akci\u011fer kanseri tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7abilecek yenilik\u00e7i bir tedavi ile g\u00fcndemde.\u00a0BioNTech’in OncoC4<\/strong> ile birlikte y\u00fcr\u00fctt\u00fc\u011f\u00fc \u00e7al\u0131\u015fmada elde edilen sonu\u00e7lar,\u00a0skuam\u00f6z tip k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri (sqNSCLC) hastalar\u0131nda \u00f6l\u00fcm riskini neredeyse yar\u0131 yar\u0131ya azalt\u0131yor<\/strong>. <\/figure>\n

\u0130ki \u015firket, ge\u00e7ti\u011fimiz g\u00fcnlerde Chicago\u2019da d\u00fczenlenen bir onkoloji konferans\u0131nda, akci\u011fer kanserinin tedavisine y\u00f6nelik \u00e7al\u0131\u015fman\u0131n \u201cdoz do\u011frulama\u201d a\u015famas\u0131na ait sonu\u00e7lar\u0131 payla\u015ft\u0131. A\u00e7\u0131klanan verilere g\u00f6re deneysel imm\u00fcnoterapi ilac\u0131 Gotistobart<\/strong>, daha \u00f6nce tedavi alm\u0131\u015f metastatik skuam\u00f6z NSCLC (k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri) hastalar\u0131nda \u00f6l\u00fcm riskini standart Docetaxel kemoterapisine k\u0131yasla y\u00fczde 54 oran\u0131nda azaltmay\u0131 ba\u015fard\u0131.<\/strong>\u00a0Metastas ya\u015fam\u0131\u015f hastalar tedavi se\u00e7enekleri hepten azald\u0131\u011f\u0131 i\u00e7in, BioNTech’in bu yeni ilac\u0131 en \u00e7ok ihtiya\u00e7 duyan gruplardan birine umut olabilir.<\/p>\n

Metastatik skuam\u00f6z tip k\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri (sqNSCLC) hastalar\u0131nda, \u00f6zellikle \u00f6nceki tedavilerden sonra hastal\u0131k ilerlediyse, medyan sa\u011fkal\u0131m \u00e7o\u011fu zaman 8\u201310 ay aral\u0131\u011f\u0131nda g\u00f6r\u00fcl\u00fcyor. Yani bu s\u00fcre i\u00e7inde hastalar\u0131n yakla\u015f\u0131k yar\u0131s\u0131 hayat\u0131n\u0131 kaybetmi\u015f oluyor.\u00a0Gotistobart verilen hastalarda ise 14.5 ayd\u0131r devam eden takip s\u00fcrecinde hen\u00fcz medyan sa\u011fkal\u0131m olu\u015fmad\u0131.<\/strong>\u00a0Gotistobart, y\u00fczde 63.1’lik y\u0131ll\u0131k sa\u011fkal\u0131m oran\u0131yla, ayn\u0131 d\u00f6nemde y\u00fczde 30.3 sa\u011fkal\u0131m oran\u0131na ula\u015fan kemoterapinin \u00e7ok \u00f6n\u00fcnde bir performans sergiledi. \u00c7al\u0131\u015fman\u0131n ba\u015f ara\u015ft\u0131rmac\u0131s\u0131 Prof. Byoung Chul Cho<\/strong>, ileri evre skuam\u00f6z NSCLC\u2019nin genellikle bir y\u0131l\u0131n alt\u0131nda sa\u011fkal\u0131m s\u00fcresiyle seyretti\u011fini hat\u0131rlatarak, \u201c15 aya yak\u0131n takipte medyan sa\u011fkal\u0131m\u0131n h\u00e2l\u00e2 g\u00f6r\u00fclmemi\u015f olmas\u0131 son derece cesaret verici\u201d ifadelerini kulland\u0131.<\/p>\n

Gotistobart, pH-duyarl\u0131 Bir Monoklonal Antikor Olarak Tasarland\u0131<\/b><\/p>\n

\u0130la\u00e7, t\u00fcm\u00f6r mikro\u00e7evresine \u00f6zg\u00fc d\u00fc\u015f\u00fck pH ko\u015fullar\u0131nda aktifle\u015fen bir monoklonal antikor olarak tasarland\u0131; b\u00f6ylece normal dokularda ba\u011f\u0131\u015f\u0131kl\u0131k sistemini bask\u0131layan T h\u00fccrelerini hedeflemekten ka\u00e7\u0131n\u0131rken, asidik yap\u0131s\u0131yla bilinen t\u00fcm\u00f6r b\u00f6lgesinde se\u00e7ici olarak devreye giriyor.<\/strong> Bu mekanizma, \u00f6zellikle imm\u00fcn yan\u0131ts\u0131zl\u0131\u011f\u0131 art\u0131ran d\u00fczenleyici T h\u00fccrelerini (Treg) bask\u0131lamak ya da ortadan kald\u0131rmak \u00fczerine kurulu. Treg\u2019lerin t\u00fcm\u00f6r i\u00e7inde yo\u011funla\u015fmas\u0131, kanserin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden \u201csaklanmas\u0131na\u201d neden olan temel s\u00fcre\u00e7lerden biri oldu\u011fundan, Gotistobart\u2019\u0131n bu h\u00fccrelere kar\u015f\u0131 mikro\u00e7evre-se\u00e7ici bir blokaj uygulamas\u0131, hem etkinlik hem de g\u00fcvenlik a\u00e7\u0131s\u0131ndan \u00f6nemli bir avantaj sa\u011fl\u0131yo<\/strong>r. B\u00f6ylece ila\u00e7, mevcut imm\u00fcnoterapilerin aksine sistemik imm\u00fcn aktivasyonu a\u015f\u0131r\u0131 derecede art\u0131rmadan, t\u00fcm\u00f6r\u00fcn ba\u011f\u0131\u015f\u0131kl\u0131k taraf\u0131ndan tan\u0131n\u0131p yok edilmesini kolayla\u015ft\u0131r\u0131yor.<\/p>\n

Bunu yaparken CTLA-4 geri d\u00f6n\u00fc\u015f\u00fcm\u00fcn\u00fc koruyarak klasik CTLA-4 inhibit\u00f6rlerinin (\u00f6rne\u011fin ipilimumab) yol a\u00e7t\u0131\u011f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k kaynakl\u0131 a\u011f\u0131r yan etkileri de azalt\u0131yor<\/strong>. Tedaviye ba\u011fl\u0131 ciddi (grade 3 ve \u00fczeri) yan etkiler gotistobart kolunda y\u00fczde 42.2, docetaxel (kemoterapi) kolunda ise y\u00fczde 48.8 olarak raporland\u0131. BioNTech ve OncoC4, bu mekanizman\u0131n t\u00fcm\u00f6r\u00fc bask\u0131layan ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini engellerken daha dengeli bir genel tolerans profili sundu\u011funu belirtiyor.<\/p>\n

Gotistobart \u015fu anda Faz 3 \u00e7al\u0131\u015fmas\u0131n\u0131n kritik a\u015famas\u0131nda de\u011ferlendiriliyor. \u0130lac\u0131n bu t\u00fcr akci\u011fer kanserlerinin tedavisinde<\/strong>\u00a0ger\u00e7ekten yeni bir standart h\u00e2line gelip gelmeyece\u011fini bu geni\u015f \u00e7apl\u0131 sonu\u00e7lar belirleyecek.<\/strong>\u00a0ABD’nin bu ilaca Fast Track ve Breakthrough Therapy gibi h\u0131zland\u0131r\u0131c\u0131 stat\u00fcler vermi\u015f olmas\u0131, d\u00fczenleyici kurumlar\u0131n ilaca ilgi g\u00f6sterdi\u011fini ortaya koyuyor; ancak onay s\u00fcreci i\u00e7in Faz 3 verilerinin tamamlanmas\u0131 \u015fart. Yine de \u015fimdiye kadar a\u00e7\u0131klanan bulgular, uzun s\u00fcredir etkili bir se\u00e7ene\u011fi olmayan skuam\u00f6z NSCLC hastalar\u0131 i\u00e7in tedavi yakla\u015f\u0131m\u0131n\u0131 kayda de\u011fer bi\u00e7imde de\u011fi\u015ftirebilecek g\u00fc\u00e7l\u00fc bir potansiyele i\u015faret ediyor.<\/p>\n\n

Kaynak\u00a0 :\u00a0https:\/\/www.donanimhaber.com\/biontech-in-akciger-kanseri-ilaci-olum-oranini-yariya-indirdi–199584<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Geli\u015ftirdi\u011fi Covid a\u015f\u0131s\u0131yla bir d\u00f6nem ad\u0131ndan s\u0131k\u00e7a s\u00f6z ettiren Alman biyoteknoloji \u015firketi BioNTech, \u015fimdi de akci\u011fer kanseri tedavisinde \u00e7\u0131\u011f\u0131r a\u00e7abilecek yenilik\u00e7i bir tedavi ile g\u00fcndemde.\u00a0BioNTech’in OncoC4 ile birlikte y\u00fcr\u00fctt\u00fc\u011f\u00fc \u00e7al\u0131\u015fmada …<\/p>\n","protected":false},"author":1,"featured_media":153218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[5364,10224,4228,641,357],"class_list":["post-153217","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-teknoloji","tag-akciger-kanseri","tag-bagisiklik","tag-hastalar","tag-sure","tag-tedavi"],"_links":{"self":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/153217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/comments?post=153217"}],"version-history":[{"count":1,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/153217\/revisions"}],"predecessor-version":[{"id":153220,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/posts\/153217\/revisions\/153220"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/media\/153218"}],"wp:attachment":[{"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/media?parent=153217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/categories?post=153217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kamucalisani.net\/index.php\/wp-json\/wp\/v2\/tags?post=153217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}